| Not Yet Recruiting | A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Livi NCT07089680 | Pfizer | — |
| Active Not Recruiting | A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 an NCT06923137 | Pfizer | — |
| Withdrawn | A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weak NCT05545319 | Pfizer | Phase 2 |
| Completed | An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are NCT05594147 | Bayer | — |
| Completed | A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in COVID-19 Pat NCT05659602 | Beijing Ditan Hospital | N/A |
| Terminated | A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess t NCT05375760 | AstraZeneca | Phase 2 |
| Completed | Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients NCT05364671 | Materia Medica Holding | Phase 3 |
| Completed | A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults NCT05184062 | AstraZeneca | Phase 2 |
| Completed | A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults NCT05437289 | AstraZeneca | Phase 1 |
| Withdrawn | COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, NCT04848467 | Bayer | Phase 3 |
| Terminated | Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222 NCT04877743 | AstraZeneca | — |
| Completed | A Study to Evaluate the Efficacy and Safety of Prothione™ Capsules for Mild to Moderate Coronavirus Disease 20 NCT04742725 | Prothione, LLC | Phase 2 |
| Terminated | COVID-19 and Anti-CD14 Treatment Trial NCT04391309 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Terminated | Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in NCT04638634 | CSL Behring | Phase 1 |
| Completed | Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combina NCT04644120 | AbbVie | Phase 1 |
| Terminated | Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans NCT04649515 | Tychan Pte Ltd. | Phase 3 |
| Completed | COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C NCT04588363 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects NCT04516564 | Akesobio Australia Pty Ltd | Phase 1 |
| Unknown | Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients NCT04395170 | Lifefactors Zona Franca, SAS | Phase 2 / Phase 3 |
| Withdrawn | CSL324 in COVID-19 NCT04519424 | CSL Behring | Phase 2 |
| Terminated | A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and NCT04508023 | Janssen Research & Development, LLC | Phase 3 |
| Completed | Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chines NCT04483375 | Sinocelltech Ltd. | Phase 1 |
| Terminated | Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure NCT04389840 | Jazz Pharmaceuticals | Phase 2 / Phase 3 |
| Withdrawn | Frespaciguat (MK-5475) in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009) NCT04425733 | Merck Sharp & Dohme LLC | Phase 1 |
| Unknown | Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers NCT04438837 | Rambam Health Care Campus | N/A |
| Completed | Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) NCT04409509 | CSL Behring | Phase 2 |
| Completed | Safety of TY027, a Treatment for COVID-19, in Humans NCT04429529 | Tychan Pte Ltd. | Phase 1 |
| Completed | Collection of Anti-SARS-CoV-2 Immune Plasma NCT04344977 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression. NCT04374526 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 2 / Phase 3 |
| Completed | Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19 NCT04545047 | VA Office of Research and Development | — |
| Completed | Immunophenotyping Assessment in a COVID-19 Cohort NCT04378777 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | COVID-19: Human Epidemiology and Response to SARS-CoV-2 NCT04375761 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Evaluation of Silver Nanoparticles for the Prevention of COVID-19 NCT04894409 | Cluster de Bioeconomia de Baja California, A.C | N/A |
| Completed | Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007) NCT04317040 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 |
| Completed | Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency NCT04403932 | Hospital San Carlos, Madrid | — |
| Completed | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19 NCT04341116 | I-Mab Biopharma US Limited | Phase 2 / Phase 3 |
| Completed | Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID- NCT04473170 | Abu Dhabi Stem Cells Center | Phase 1 / Phase 2 |
| Unknown | Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-1 NCT04346368 | Guangzhou Institute of Respiratory Disease | Phase 1 / Phase 2 |
| Completed | BCG Vaccination to Protect Healthcare Workers Against COVID-19 NCT04327206 | Murdoch Childrens Research Institute | Phase 3 |
| Completed | Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia NCT04275245 | Tang-Du Hospital | Phase 1 / Phase 2 |